Skip to main content
Caplight Logo









Orakl Oncology

Orakl Oncology

Private
VillejuifHealthcare & Life Scienceshttps://www.orakl-oncology.com/

Last Round

Seed

Dec 3, 2024

Total Funding Raised

$14.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Orakl Oncology is a biotechnology company that develops an AI-driven platform using patient-derived tumor avatars to accelerate cancer drug discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

digital twintechbiodrug discoveryAI drug discoveryprecision medicinepredictive modelingoncology AIclinical trial designmulti-omicsin silico trialstumor avatarscomputational biologypreclinical researchbiotech SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orakl Oncology Comparables

Compare Orakl Oncology with similar companies based on industry and business-model similarity.

Orakl Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TwinEdge Bioscience
83%
DeepLife
83%
QuantHealth
82%

Orakl Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 3, 2024
Pre SeedOct 4, 2023

Key People

Founding team and executive leadership

Gustave Ronteix

Co-Founder And CTO

Founding Team

Orakl Oncology Investors

Notable investors and investment history

Orakl Oncology investors
InvestorRounds
Verve VenturesSeed, Pre Seed
SingularSeed
SpeedinvestSeed, Pre Seed
HCVCSeed, Pre Seed
BpifranceSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 3, 2026

    Open roles increased to 121, 3.46x headcount.

  • Jul 20, 2026

    Open roles increased to 116, 3.6x the trailing average.

Orakl Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orakl Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orakl Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersVillejuif
Employee Range36
Year Founded2023
Last FundingDec 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?